Keep pulling the thread on Brian Kennedy.
During aging, baseline levels of mTOR activity increase, preventing the pathway from being fully turned off and disrupting its dynamic range.
Reducing mTOR signaling has been shown to extend lifespan across a wide range of species.
A key mechanism in aging is a feed-forward loop where elevated mTOR activity drives chronic inflammation, which in turn further increases mTOR signaling.
All interventions that are known to extend lifespan also reduce chronic inflammation.
Current longevity interventions are predicted to provide five to ten years of additional healthspan but are unlikely to change the maximum human lifespan.
A clinical study is underway in Singapore with 150-200 healthy individuals aged 40-60, involving a six-month intervention with 5mg of rapamycin once a week.
A new biological aging clock based on clinical chemistry from the NHANES dataset predicts mortality better than any other parameter in the dataset, including ASCVD risk scores and second-generation methylation clocks.
The creation of Calico by Google's parent company Alphabet generated significant publicity for the longevity field and attracted interest from Silicon Valley.
The failure of GSK's resveratrol program, acquired around 2007, likely slowed down investor interest in the longevity sector.
Brian Kennedy's academic lab in Singapore utilizes a research pipeline of animal models including yeast, worms, flies, killifish, and mice to validate longevity interventions before human trials.
The research program led by Brian Kennedy in Singapore includes approximately 35 principal investigators studying aging and related areas such as Alzheimer's disease and sleep.
The first international conference on "gerophysics" was recently held in Singapore to apply principles from theoretical physics to model the aging process.